Travere Therapeutics/$TVTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
- Ticker
- $TVTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 497
- Headquarters
- San Diego, United States
- Website
- www.travere.com
TVTX Metrics
BasicAdvanced
$5B
-
-$1.31
1.12
-
Price and volume
Market cap
$5B
Beta
1.12
52-week high
$68.73
52-week low
$22.59
Average daily volume
2.3M
Financial strength
Current ratio
3.003
Quick ratio
2.747
Long term debt to equity
27.003
Total debt to equity
27.283
Interest coverage (TTM)
-2.30%
Profitability
EBITDA (TTM)
32.403
Gross margin (TTM)
61.07%
Net profit margin (TTM)
-18.66%
Operating margin (TTM)
-3.13%
Effective tax rate (TTM)
3.32%
Revenue per employee (TTM)
$1,310,000
Management effectiveness
Return on assets (TTM)
-1.84%
Return on equity (TTM)
-321.22%
Valuation
Price to revenue (TTM)
7.393
Price to book
220.25
Price to tangible book (TTM)
-35.15
Price to free cash flow (TTM)
-175.72
Free cash flow yield (TTM)
-0.57%
Free cash flow per share (TTM)
-0.296
Growth
Revenue change (TTM)
49.38%
Earnings per share change (TTM)
29.28%
3-year revenue growth (CAGR)
71.30%
10-year revenue growth (CAGR)
17.78%
3-year earnings per share growth (CAGR)
2.39%
10-year earnings per share growth (CAGR)
1.41%
What the Analysts think about TVTX
Analyst ratings (Buy, Hold, Sell) for Travere Therapeutics stock.
Analyst projections of the future price of Travere Therapeutics stock.
Bulls say / Bears say
FILSPARI sales rose 120% year on year to $200.2 million in Q3 2026, with demand across IgAN and FSGS. This gives Travere a rapidly growing commercial base rather than leaving its prospects dependent only on pipeline milestones. (Travere Therapeutics)
The FDA made FILSPARI the first and only approved medicine for FSGS in adults and children aged eight and over without nephrotic syndrome. In Q3, 40% of first-time FSGS prescribers were new to the brand, suggesting scope to reach more doctors and patients. (Travere Therapeutics, The Motley Fool)
Pegtibatinase is advancing in the Phase 3 HARMONY trial, with topline results expected in the second half of 2027. A successful result could broaden Travere beyond kidney disease, as the company aims to develop the first disease-modifying treatment for classical HCU. (Travere Therapeutics)
The FDA said Travere’s promotional claims overstated evidence that FILSPARI preserves kidney function and understated safety risks. The drug carries boxed warnings for liver toxicity and harm to an unborn baby, which may weigh on prescribing and require careful monitoring. (MM+M)
Treatment options for IgAN are expanding, and combined IgAN and FSGS patient start forms eased from 2,012 in Q2 to 1,932 in Q3. Management said doctors are weighing treatment sequences and combinations, creating uncertainty around future starts. (Travere Therapeutics, The Motley Fool)
Travere posted a $52.3 million GAAP loss in Q3, compared with net income a year earlier, as research and commercial costs rose and a large licensing-related charge hit earnings. The company’s growth is therefore not yet translating into consistent profits. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
TVTX Financial Performance
Revenues and expenses
TVTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
TVTX News
AllArticlesVideos
Funds containing TVTX
Fund name | Fund size | $TVTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.30% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.30% |
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.15% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.15% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.